10/20/2021 Cerba Healthcare (CERBA) EUR500m 144A/Reg S notes 2-part. Via DB (sole physical)/GS/JPM/UBS jt lead books/BNP/CA/HSBC/Mediobanca/Mizuho/Nomura/UniCredit jt books. No reg rights. List Lux. NY law. Settles 10/26 (T+4).
- Chrome Bidco SAS EUR300m add-on to its 3.50 sr sec notes due 05/31/28 (6.5y). NC2.5 (05/31/24) (MWC B+50bp), then at 101.750, 100.875, 100. Equity claw: 2.5y 40% at 103.50. Special call: 10% per year the first 2.5 years at 103. B1/B (stable/stable). Reg S ISIN: XS2343000241. Immediately 144A fungible (Reg S after 40 days) with the EUR420m issue priced 05/12/21. Px talk: 99.25-99.75. Final terms: EUR300m 3.50% add-on at 99.75. Priced: 3.50% add-on at 99.75, 3.54% YTM. +390bp vs DBR 0.25% 08/15/28.
- Chrome Holdco SAS EUR200m add-on to its 5.00% sr unsec notes due 05/31/29 (7.5y). NC2.5 (05/31/24) (MWC B+50bp), then at 102.50, 101.25, 100. Equity claw: 2.5y 40% at 105.00. Caa1/CCC+ (stable/stable). Reg S ISIN: XS2343001991. Immediately 144A fungible (Reg S after 40 days) with the EUR325m issue priced 05/12/21. Px talk 99.50-par. Final terms: EUR200m 5.00% add-on at 100. Priced: 5.00% add-on at 100, 5.00% YTM. +528bp vs DBR 0% due 08/15/29.
Roadshow 10/18-19 (investor call at 11am UKT 10/18). Books closed at 12pm UKT 10/20. UOP: along with EUR350m (up from EUR300m) term loan B add-on via GS/JPM/UBS+, to fund the acquisition of Lifebrain from Investindustrial for around EUR1.2bn enterprise value (EUR675m equity purchase and EUR520m debt refi) (EUR50m TLB upsize for cash on the B/S). The equity sponsors, EQT and PSP Investments, will contribute EUR466m in new equity. Biz: an international network of medical biological laboratories providing medical diagnostic services. HQ: Issy-les-Moulineaux, France. (Acquisition announced 07/21/21).
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.